Li, Kai-Chun
Girardi, Enrico http://orcid.org/0000-0003-3508-2723
Kartnig, Felix
Grosche, Sarah
Pemovska, Tea http://orcid.org/0000-0003-2951-4905
Bigenzahn, Johannes W.
Goldmann, Ulrich http://orcid.org/0000-0003-1120-6912
Sedlyarov, Vitaly
Bensimon, Ariel
Schick, Sandra http://orcid.org/0000-0002-4061-2381
Lin, Jung-Ming G.
Gürtl, Bettina
Reil, Daniela
Klavins, Kristaps
Kubicek, Stefan http://orcid.org/0000-0003-0855-8343
Sdelci, Sara http://orcid.org/0000-0003-1330-4364
Superti-Furga, Giulio http://orcid.org/0000-0002-0570-1768
Funding for this research was provided by:
European Research Council
Department of Education and Training | Australian Research Council (Marie Sk1odowska-Curie Action Fellowship 661491)
European Commission (Marie Sk1odowska-Curie Action Fellowship 661491)
Peter and Traudl Engelhorn Foundation
European Molecular Biology Organization
Austrian Science Fund (FWF SFB F4711, FWF SFB F4711, I2192-B22 ERASE, FWF F4701, FWF SFB F4711)
Österreichischen Akademie der Wissenschaften
Article History
Received: 8 June 2020
Accepted: 24 March 2021
First Online: 10 May 2021
Competing interests
: G.S.-F., S.K. and A.B. are founders and own shares of Solgate GmbH, an SLC-focused company. S. Sdelci and S.K. have filed patent application WO 2018/087401 A2 on synergistic combinations with BRD4 inhibitors. The other authors declare no competing interests.